Usoro ọgwụgwọ ACEA
ACEA Therapeutics, nke dị na San Diego, California bụ enyemaka nke Sorrento nwere kpam kpam. ACEA Therapeutics na-agba mbọ ịzụlite na ịnye ọgwụgwọ ọhụrụ iji meziwanye ndụ ndị ọrịa nwere ọrịa na-eyi ndụ egwu.
Ngwakọta ụzọ anyị, Abivertinib, obere ihe mgbochi molecule kinase, na-enyocha ugbu a site na China Food and Drug Administration (CFDA) maka ọgwụgwọ nke ndị ọrịa nwere ọrịa cancer akpa ume na-abụghị obere cell (NSCLC) nwere mgbanwe EGFR T790M. Ọ dịkwa na nnwale ụlọ ọgwụ ịgwọ ndị ọrịa nwere Covid-19 n'ụlọ ọgwụ na Brazil na US na-eduzi Sorrento Therapeutics. Obere obere molikula kinase inhibitor nke ACEA, AC0058, abanyela na mmepe Phase 1B na US maka ọgwụgwọ nke lupus erythematosus (SLE).
N'akụkụ otu R&D siri ike, ACEA ewepụtala nrụpụta ọgwụ na ikike azụmaahịa na China iji kwado uto ogologo oge anyị. Akụrụngwa a na-enye anyị ikike ka ukwuu n'usoro ọkọnọ anyị iji hụ na ebugara ndị ọrịa n'oge.
SCILEX
SCILEX HOLDING COMPANY ("Scilex"), onye enyemaka nke ọtụtụ ndị nwere na Sorrento, raara onwe ya nye maka mmepe na ịzụ ahịa ngwaahịa nchịkwa mgbu. Ngwaahịa isi ụlọ ọrụ ZTlido® (Sistemụ Topical lidocaine 1.8%), bụ ngwaahịa ọgwụ lidocaine edepụtara aha nke US Food and Drug Administration kwadoro maka enyemaka nke mgbu metụtara Post-Herpetic Neuralgia (PHN), nke bụ ụdị mgbu akwara post-shingles.
Scilex's SP-102 (10 mg dexamethasone sodium phosphate gel), ma ọ bụ SEMDEXA ™, maka ọgwụgwọ Lumbar Radicular Pain nọ na-emecha nyocha ụlọ ọgwụ nke Phase III. Ụlọ ọrụ ahụ na-atụ anya ka SP-102 bụrụ onye mbụ FDA kwadoro na-abụghị opioid epidural injections iji na-emeso mgbu radicular lumbosacral, ma ọ bụ sciatica, na-enwe ike dochie 10 ka 11 nde off-label epidural steroid injections nke a na-enye kwa afọ na US.
Gị Site
Bioserv
Bioserv, nke dị na San Diego, California bụ enyemaka nke Sorrento nwere kpam kpam. Tọrọ ntọala na 1988, nzukọ a bụ onye na-eweta ọrụ nkwekọrịta cGMP na-eweta ọrụ nwere ihe karịrị 35,000 square ụkwụ nke akụrụngwa ndị isi ikike ha gbadoro ụkwụ na usoro aseptị na-abụghị nke aseptic; filtration; njuputa; nkwụsị; ọrụ lyophilization; akara; mkpọkọta ngwongwo emechara; kitting na nkwakọ ngwaahịa; yana nchekwa nchekwa okpomọkụ na ọrụ nkesa a na-achịkwa iji kwado ngwaahịa ọgwụ Pre-Clinical, Phase I na II Clinical Trial, reagents ngwaọrụ ahụike, reagents na ngwa nyocha ahụike, yana reagents sayensị ndụ.
Gị Site
Concortis-Levena
Na 2008, Concortis Biosystems e hiwere na ebumnobi na-ejere ndị sayensị na ọgwụ obodo na elu mma antibody ọgwụ conjugate (ADC) reagents na ọrụ. Na 2013, Sorrento nwetara Concortis, na-ekepụta ụlọ ọrụ ADC kacha elu. Ngwakọta G-MAB ™ (ọbá akwụkwọ mgbochi mmadụ zuru oke) yana nsị nke Concortis, njikọ njikọ na ụzọ njikọ nwere ike iwepụta ndị na-eduzi ụlọ ọrụ, ọgbọ nke atọ ADC.
Concortis na-enyocha ihe karịrị 20 nhọrọ ADC dị iche iche (na-ahụ maka ụlọ ọgwụ) yana ngwa na oncology na gafere. N'October 19, 2015, Sorrento kwupụtara mmepụta nke Levena Biopharma dị ka ụlọ ọrụ nweere onwe ya iji nye ahịa ọtụtụ ọrụ ADC site na mmalite nke ọrụ ADC site na mmepụta cGMP nke ADCs ruo oge I / II ọmụmụ ụlọ ọgwụ. Maka ozi zuru ezu, biko gaa na www.levenabiopharma.com
Gị Site
Akụkọ ihe mere eme nke SmartPharm Therapeutics, Inc
SmartPharm Therapeutics, Inc. ("SmartPharm"), enyemaka nwere kpam kpam. Sorrento Therapeutics, Inc. (Nasdaq: SRNE), bụ ụlọ ọrụ mmepe nke biopharmaceutical nke na-elekwasị anya na ọgbọ na-abịa, usoro ọgwụgwọ mkpụrụ ndụ na-abụghị nke nje maka ọgwụgwọ ọrịa siri ike ma ọ bụ nke na-adịghị ahụkebe na ọhụụ nke ịmepụta "biologics si n'ime." SmartPharm na-emepụta akwụkwọ akụkọ ugbu a, DNA-encoded monoclonal antibody iji gbochie ọrịa SARS-CoV-2, nje na-akpata COVID-19 n'okpuru nkwekọrịta ya na Defence Advanced Research Projects Agency nke US Department of Defense. SmartPharm malitere ọrụ na 2018 ma ọ bụ isi na Cambridge, MA, USA.
Gị Site
Igbe anụmanụ ahụike
Ark Animal Health bụ enyemaka nke Sorrento nwere kpam kpam. Emebere ụgbọ mmiri na 2014 iji weta ihe ngwọta ọhụrụ sitere na ọrụ nyocha na mmepe mmadụ nke Sorrento n'ahịa anụmanụ. A na-ahazi ya ka ọ bụrụ nzukọ zuru oke na nke nwere onwe ya ozugbo ọ ruru ọkwa azụmahịa (ngwaahịa dị njikere ịnweta nkwado FDA).
Mmemme mmepe nke igbe (ARK-001) bụ otu dose resiniferatoxin (RTX) ngwọta injectable na-adịghị mma. ARK-001 anatala FDA CVM (Center for Veterinary Medicine) MUMS (obere iji / obere ụdị) aha maka njikwa ọrịa kansa ọkpụkpụ na nkịta. Ọrụ ndị ọzọ na-agụnye ihe ngosi ndị ọzọ maka RTX na mpaghara dị ka ihe mgbu na-adịghị ala ala na ụmụ anụmanụ ibe, nhụjuanya neuropathic na ịnyịnya, na cystitis idiopathic na nwamba, yana ịchọta ohere mmepe na mpaghara ọrịa na-efe efe ma ọ bụ ọgwụgwọ ọrịa cancer.
Gị Site